Literature DB >> 27622030

The ecto-ATPDase CD39 is involved in the acquisition of the immunoregulatory phenotype by M-CSF-macrophages and ovarian cancer tumor-associated macrophages: Regulatory role of IL-27.

Sènan M d'Almeida1, Gilles Kauffenstein2, Charlotte Roy2, Laetitia Basset1, Loukas Papargyris1, Daniel Henrion2, Véronique Catros3, Norbert Ifrah4, Philippe Descamps5, Anne Croue6, Pascale Jeannin7, Marc Grégoire8, Yves Delneste7, Julie Tabiasco1.   

Abstract

Tumor-associated macrophages (TAM) are immunosuppressive cells that can massively accumulate in the tumor microenvironment. In patients with ovarian cancer, their density is correlated with poor prognosis. Targeting mediators that control the generation or the differentiation of immunoregulatory macrophages represents a therapeutic challenge to overcome tumor-associated immunosuppression. The ectonucleotidase CD39 hydrolyzes ATP into extracellular adenosine that exhibits potent immunosuppressive properties when signaling through the A2A adenosine receptor. We report here that CD14(+) CD163(+) TAM isolated from ovarian cancer patients and macrophages generated in vitro with M-CSF, express high levels of the membrane ectonucleotidase CD39 compared to classically activated macrophages. The CD39 inhibitor POM-1 and adenosine deaminase (ADA) diminished some of the immunosuppressive functions of CD14(high) CD163(high) CD39(high) macrophages, such as IL-10 secretion. We identified the cytokine IL-27, secreted by tumor-infiltrating neutrophils, located close to infiltrating CD163(+) macrophages, as a major rheostat of CD39 expression and consequently, on the acquisition of immunoregulatory properties by macrophages. Accordingly, the depletion of IL-27 downregulated CD39 and PD-L1 expression as well as IL-10 secretion by M-CSF-macrophages. Collectively, these data suggest that CD39, drived by IL-27 and CD115 ligands in ovarian cancer, maintains the immunosuppressive phenotype of TAM. This work brings new information on the acquisition of immunosuppressive properties by tumor-infiltrating macrophages.

Entities:  

Keywords:  ATP; CD39; IL-10; IL-27; M-CSF; adenosine; ovarian cancer; tumor-associated macrophages

Year:  2016        PMID: 27622030      PMCID: PMC5006905          DOI: 10.1080/2162402X.2016.1178025

Source DB:  PubMed          Journal:  Oncoimmunology        ISSN: 2162-4011            Impact factor:   8.110


  72 in total

1.  Th1/Th2 cells, their associated molecules and role in pathophysiology.

Authors:  P Romagnani; F Annunziato; M P Piccinni; E Maggi; S Romagnani
Journal:  Eur Cytokine Netw       Date:  2000-09       Impact factor: 2.737

Review 2.  Macrophage plasticity and polarization: in vivo veritas.

Authors:  Antonio Sica; Alberto Mantovani
Journal:  J Clin Invest       Date:  2012-03-01       Impact factor: 14.808

3.  IL-27 acts on DCs to suppress the T cell response and autoimmunity by inducing expression of the immunoregulatory molecule CD39.

Authors:  Ivan D Mascanfroni; Ada Yeste; Silvio M Vieira; Evan J Burns; Bonny Patel; Ido Sloma; Yan Wu; Lior Mayo; Rotem Ben-Hamo; Sol Efroni; Vijay K Kuchroo; Simon C Robson; Francisco J Quintana
Journal:  Nat Immunol       Date:  2013-09-01       Impact factor: 25.606

4.  NTPDase1 governs P2X7-dependent functions in murine macrophages.

Authors:  Sébastien A Lévesque; Filip Kukulski; Keiichi Enjyoji; Simon C Robson; Jean Sévigny
Journal:  Eur J Immunol       Date:  2010-05       Impact factor: 5.532

Review 5.  Ecto-enzyme and signaling functions of lymphocyte CD73.

Authors:  R Resta; Y Yamashita; L F Thompson
Journal:  Immunol Rev       Date:  1998-02       Impact factor: 12.988

6.  A2A adenosine receptor protects tumors from antitumor T cells.

Authors:  Akio Ohta; Elieser Gorelik; Simon J Prasad; Franca Ronchese; Dmitriy Lukashev; Michael K K Wong; Xiaojun Huang; Sheila Caldwell; Kebin Liu; Patrick Smith; Jiang-Fan Chen; Edwin K Jackson; Sergey Apasov; Scott Abrams; Michail Sitkovsky
Journal:  Proc Natl Acad Sci U S A       Date:  2006-08-17       Impact factor: 11.205

7.  Inhibition of CD39 enzymatic function at the surface of tumor cells alleviates their immunosuppressive activity.

Authors:  Jeremy Bastid; Anne Regairaz; Nathalie Bonnefoy; Cécile Déjou; Jérôme Giustiniani; Caroline Laheurte; Stéphanie Cochaud; Emilie Laprevotte; Elisa Funck-Brentano; Patrice Hemon; Laurent Gros; Nicole Bec; Christian Larroque; Gilles Alberici; Armand Bensussan; Jean-François Eliaou
Journal:  Cancer Immunol Res       Date:  2014-11-17       Impact factor: 11.151

Review 8.  Shaping of monocyte and macrophage function by adenosine receptors.

Authors:  György Haskó; Pál Pacher; Edwin A Deitch; E Sylvester Vizi
Journal:  Pharmacol Ther       Date:  2006-09-14       Impact factor: 12.310

9.  Myeloid expression of adenosine A2A receptor suppresses T and NK cell responses in the solid tumor microenvironment.

Authors:  Caglar Cekic; Yuan-Ji Day; Duygu Sag; Joel Linden
Journal:  Cancer Res       Date:  2014-11-06       Impact factor: 12.701

10.  Role of A2a extracellular adenosine receptor-mediated signaling in adenosine-mediated inhibition of T-cell activation and expansion.

Authors:  S Huang; S Apasov; M Koshiba; M Sitkovsky
Journal:  Blood       Date:  1997-08-15       Impact factor: 22.113

View more
  21 in total

1.  Prostaglandin E2-mediated adenosinergic effects on CD14+ cells: Self-amplifying immunosuppression in cancer.

Authors:  Saly Al-Taei; Josephine Salimu; Lisa K Spary; Aled Clayton; Jason F Lester; Zsuzsanna Tabi
Journal:  Oncoimmunology       Date:  2016-12-08       Impact factor: 8.110

2.  Loss of vascular expression of nucleoside triphosphate diphosphohydrolase-1/CD39 in hypertension.

Authors:  Charlotte Roy; Julie Tabiasco; Antoine Caillon; Yves Delneste; Jean Merot; Julie Favre; Anne Laure Guihot; Ludovic Martin; Daniele C Nascimento; Bernhard Ryffel; Simon C Robson; Jean Sévigny; Daniel Henrion; Gilles Kauffenstein
Journal:  Purinergic Signal       Date:  2017-12-13       Impact factor: 3.765

Review 3.  The pleiotropic mode and molecular mechanism of macrophages in promoting tumor progression and metastasis.

Authors:  Xingxing Zhang; Wenxiu Bai; Lisha Hu; Hualan Ha; Yuelin Du; Wei Xiong; Hongbo Wang; Panfeng Shang
Journal:  Clin Transl Oncol       Date:  2022-09-07       Impact factor: 3.340

4.  Glycoengineered anti-CD39 promotes anticancer responses by depleting suppressive cells and inhibiting angiogenesis in tumor models.

Authors:  Haohai Zhang; Lili Feng; Paola de Andrade Mello; Changchuin Mao; Richard Near; Eva Csizmadia; Leo Li-Ying Chan; Keiichi Enjyoji; Wenda Gao; Haitao Zhao; Simon C Robson
Journal:  J Clin Invest       Date:  2022-07-01       Impact factor: 19.456

5.  The effects of CD14 and IL-27 on induction of endotoxin tolerance in human monocytes and macrophages.

Authors:  Carlene Petes; Victoria Mintsopoulos; Renée L Finnen; Bruce W Banfield; Katrina Gee
Journal:  J Biol Chem       Date:  2018-09-21       Impact factor: 5.157

Review 6.  A review and outlook in the treatment of osteosarcoma and other deep tumors with photodynamic therapy: from basic to deep.

Authors:  Wei Yu; Jian Zhu; Yitian Wang; Junjie Wang; Weijing Fang; Kaishun Xia; Jianlin Shao; Minzu Wu; Bing Liu; Chengzhen Liang; Chengyi Ye; Huimin Tao
Journal:  Oncotarget       Date:  2017-06-13

Review 7.  Dual Roles of IL-27 in Cancer Biology and Immunotherapy.

Authors:  Marina Fabbi; Grazia Carbotti; Silvano Ferrini
Journal:  Mediators Inflamm       Date:  2017-02-01       Impact factor: 4.711

8.  Sperm Protein 17 Expression by Murine Epithelial Ovarian Cancer Cells and Its Impact on Tumor Progression.

Authors:  Qian Gao; Sue D Xiang; Kirsty Wilson; Mutsa Madondo; Andrew N Stephens; Magdalena Plebanski
Journal:  Cancers (Basel)       Date:  2018-08-20       Impact factor: 6.639

Review 9.  ATP and cancer immunosurveillance.

Authors:  Oliver Kepp; Lucillia Bezu; Takahiro Yamazaki; Francesco Di Virgilio; Mark J Smyth; Guido Kroemer; Lorenzo Galluzzi
Journal:  EMBO J       Date:  2021-06-14       Impact factor: 14.012

Review 10.  Metabolic reprograming of tumor-associated macrophages.

Authors:  Abhishek Puthenveetil; Shweta Dubey
Journal:  Ann Transl Med       Date:  2020-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.